• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 3. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331

Recent Advances in the Application of 5-Bromo-1-methyl-1H-indazole-3-carboxylic acid (CAS: 1363380-96-4) in Chemical Biology and Pharmaceutical Research

The compound 5-Bromo-1-methyl-1H-indazole-3-carboxylic acid (CAS: 1363380-96-4) has recently emerged as a key intermediate in medicinal chemistry and drug discovery. This heterocyclic scaffold has garnered significant attention due to its versatile pharmacological properties and its role as a building block for more complex bioactive molecules. Recent studies have highlighted its potential in the development of kinase inhibitors, anti-inflammatory agents, and anticancer therapeutics, positioning it as a valuable tool in modern drug design.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 5-Bromo-1-methyl-1H-indazole-3-carboxylic acid in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized this compound as a core structure, modifying it through strategic substitutions to enhance binding affinity and selectivity. The resulting derivatives showed promising activity against B-cell malignancies, with improved pharmacokinetic profiles compared to existing therapies. This work underscores the compound's importance in addressing the growing need for targeted cancer therapies.

In the field of anti-inflammatory drug development, a recent patent application (WO2023051234) disclosed novel indazole-based compounds derived from 5-Bromo-1-methyl-1H-indazole-3-carboxylic acid that exhibit potent inhibition of NLRP3 inflammasome activation. These derivatives demonstrated significant reduction in pro-inflammatory cytokine production in preclinical models of autoimmune diseases, suggesting potential applications in treating conditions such as rheumatoid arthritis and inflammatory bowel disease. The structural flexibility of the indazole core allows for fine-tuning of both potency and metabolic stability.

From a synthetic chemistry perspective, advances in the preparation of 5-Bromo-1-methyl-1H-indazole-3-carboxylic acid have been reported in Organic Process Research & Development (2023). Researchers developed a more efficient, scalable synthesis route that reduces the number of purification steps while maintaining high purity (>99%). This improvement in manufacturing process is particularly relevant for pharmaceutical companies looking to incorporate this intermediate into their drug development pipelines at commercial scale.

Emerging applications in radiopharmaceuticals have also been documented, with 5-Bromo-1-methyl-1H-indazole-3-carboxylic acid serving as a precursor for PET tracer development. A 2024 study in the European Journal of Medicinal Chemistry described the synthesis of ¹⁸F-labeled analogs for imaging protein-protein interactions in neurodegenerative diseases. The bromo substituent in particular was found to facilitate efficient radiohalogenation while maintaining the compound's favorable brain penetration properties.

As research continues to uncover new therapeutic avenues for indazole derivatives, 5-Bromo-1-methyl-1H-indazole-3-carboxylic acid remains a critical scaffold in medicinal chemistry. Its combination of synthetic accessibility, structural diversity, and biological relevance ensures its continued importance in pharmaceutical research. Future directions likely include exploration of its potential in targeted protein degradation (PROTACs) and as a warhead in covalent inhibitor design, areas that are currently transforming drug discovery paradigms.

• 660823-36-9(6-Bromo-1H-indazole-3-carboxylic acid)
• 109216-60-6(Methyl 1-methyl-1H-indazole-3-carboxylate)
• 1021859-29-9(6-Bromo-1-methyl-1H-indazole-3-carboxylic acid)
• 946427-77-6(Methyl 6-bromo-1-methyl-1H-indazole-3-carboxylate)
• 50890-83-0(1-Methyl-1H-indazole-3-carboxylic acid)
• 886368-88-3(5-Fluoro-1-methyl-1H-indazole-3-carboxylic acid)
• 885275-47-8(1-(4-Bromophenyl)-1H-indazole-3-carboxylic acid)
• 1077-94-7(5-Bromo-1H-indazole-3-carboxylic Acid)
• 701910-30-7(7-Bromo-2-methyl-2H-indazole-3-carboxylic acid)
• 1021859-33-5(6-bromo-2-methyl-2H-indazole-3-carboxylic acid)